Steroid transfer study aims to protect premature Babies' lungs
NCT ID NCT01854840
First seen Mar 08, 2026 · Last updated Apr 30, 2026 · Updated 10 times
Summary
This completed study looked at 127 pregnant women who received betamethasone (Celesten) to prevent lung problems in their premature babies. Researchers measured how much of the drug crossed the placenta and checked if it reduced the risk or severity of hyaline membrane disease, a serious breathing condition in newborns. The goal was to better understand the link between drug levels and baby outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANT WOMEN RECEIVE CELESTEN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Necker Hospital
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.